Explore more publications!

Press Releases

NOTICE TO DISREGARD --  LCX

NOTICE TO DISREGARD -- LCX

LCX Strengthens Ties with Cardano Ecosystem, Launches Token Sale for Profila’s $ZEKE Token
Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
xPortal Acquires Alphalink to Drive Innovation at the Intersection of AI and Crypto
Premier League star investigated over liking anti-LGBTQ footage

Premier League star investigated over liking anti-LGBTQ footage

The Dealmakers Spotlight Ocean Quest’s AI & Robotics Advancing Global Sustainability at Investors Roundtable in Dubai
OilXCoin's Prospectus Secures First Regulatory Approval For A Very Unique Security Token Backed by Oil & Gas
Legacy Network Powers Up Education With Major Blockchain Move – $LGCT Set To Become Global Currency Of Learning
argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
German Blockchain & AI Week 2025: Agenda BEAM – 'Bridging European and Asian Markets'
Press Statement by the Global Governance Group (3G) on its Eighteenth Ministerial Meeting on 24 September 2025

Press Statement by the Global Governance Group (3G) on its Eighteenth Ministerial Meeting on 24 September 2025

QOC Exchange Launches QOC Prime, QOC Plus, and QOC Max Apps in Europe
EU Defends Schengen as Border Controls Mount Across Bloc

EU Defends Schengen as Border Controls Mount Across Bloc

EU Reach Forty Years of Schengen Agreement

EU Reach Forty Years of Schengen Agreement

Beam Global Announces EV ARC™ System Meets CE Mark Compliance
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
Opterro, Inc. and Polytec GmbH Announce Strategic Distribution Agreement Across Eight European Countries
Ligand Reports First Quarter 2025 Financial Results
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions